NCT04077424View on ClinicalTrials.gov

Senescent Immunity in Elders and Vaccine Responses (SILVER)

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions
Flu Vaccine
Interventions
BIOLOGICAL

Fluzone-High Dose Quadrivalent

Seasonal influenza vaccination with FDA approved vaccines for this age group.

BIOLOGICAL

Fluad

Adjuvanted (MF59) inactivated influenza vaccine

BIOLOGICAL

Flublock

Recombinant hemagglutinin vaccine

Trial Locations (1)

37211

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT04077424 - Senescent Immunity in Elders and Vaccine Responses (SILVER) | Biotech Hunter | Biotech Hunter